Cañadas MP, Lloveras B, Lorincz A, Ejarque M, Font R, Bosch FX, Sanjosé S

Language: Spanish
References: 16
Page: 373-378
PDF size: 87.79 Kb.

ABSTRACT

Objective: Detection of high-risk human papillomavirus types (HPV) infection is an important tool in the screening of cervical cancer and triage of cytological abnormalities. The different techniques for detection of this cancer need to be contrasted and validated for use in population screening. Material and Methods: Cervical cell samples were collected from 166 women attending a dermatology clinic in Oviedo (Spain). We evaluated the performance of three different assays for VPH detection. The methods utilized were 1) In-house PCR-EIA using L1 consensus primers MY09/MY11, 2) A PCR-reverse line blot hybridization (PCR-LBH) that uses L1 consensus PGMY primers. 3) Hybrid Capture 2. All assays were performed blinded. The kappa statistic was used to test for global agreement between assay pairs. Results: HPV DNA was detected in 24,7%, 25,3% and 29,5% of the women, respective to the assay. The overall agreement between the in-house PCR, PCR-LBH and HC2 was (73.5%) with all kappa values between assay pairs exceeding 0.56 (p‹0.001). Conclusion: The three HPV assays were equally accurate in estimating high-risk HPV prevalence and HPV-related lesions. The method for HPV detection must be decided depending on the goals of the search (screening, follow-up or molecular studies).

REFERENCES

1. Walboomers IMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.

2. National Cancer Institute Workshop. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. JAMA 1989;262:931-934.

3. National Cancer Institute Workshop. The revised Bethesda system for reporting cervical/vaginal diagnoses. JAMA 1992;267:1892.

4. Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, Kurman RJ, et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994;102:182-187.

5. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-1610.

6. Solomon D, Schiffman M, Tarone R. ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-299.

7. Canadas MP, Martinez F, Sanjose S, Valls I, Lloveras B, Bosch FX, et al. Detection of human papillomavirus DNA by PCR in high-risk women. Validation of a protocol. Enferm Infecc Microbiol Clin 1998;16:400-403.

8. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-3027.

9. Cox JT. Evaluating the role of VPH testing for women with equivocal Papanicoalou test findings (editorial). JAMA 1999;281:1645-1647.

10. Ho L, Terry G, Londesborough P, Cuzick J, Lorenzato F, Singer A. Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears. J Med Virol 2003;69:118-121.

11. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-361.

12. Fuessel AL, He Q, Rady PL, et al. Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 2004;122(1):87-89.

13. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37(8):2508-2517.

14. Ponten J, Guo Z. Precancer of the human cervix. Cancer Surv 1998;32:201-229.

15. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, et al. Type´specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-1638.

16. Soderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. Comparison between the hybrid capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol 2005;43(7):3260-3266.